8-K/A
COLLEGIUM PHARMACEUTICAL, INC (COLL)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):March 23, 2022
COLLEGIUM PHARMACEUTICAL, INC.
(Exact name of registrant as specified in its charter)
| Virginia | 001-37372 | 03-0416362 |
|---|---|---|
| (State or other jurisdiction of <br><br>incorporation) | (Commission File <br><br>Number) | (IRS Employer Identification No.) |
| 100 Technology Center Drive | ||
| --- | ||
| Suite 300 | ||
| Stoughton, MA 02072 | ||
| (Address and Zip Code of Principal Executive Offices) |
(781) 713-3699
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.001 per share | COLL | The NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Explanatory Note
On March 23, 2022, Collegium Pharmaceutical, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial Form 8-K”) to report the completion of its acquisition (the “Acquisition”) of BioDelivery Sciences International, Inc. (“BDSI”), pursuant to an Agreement and Plan of Merger, dated as of February 14, 2022, by and among the Company, Bristol Acquisition Company, Inc., a wholly owned subsidiary of the Company, and BDSI. Upon completion of the Acquisition, BDSI became a wholly owned subsidiary of the Company.
The Company is filing this Amendment No. 1 to the Initial Form 8-K to include the historical financial statements of BDSI and pro forma condensed combined financial information required to be filed under Item 9.01 of Form 8-K. Except as provided herein, the disclosure included in the Initial Form 8-K otherwise remains unchanged.
Item 9.01. Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired
The audited consolidated financial statements of BDSI as of December 31, 2021 and 2020 and for each of the three years ended December 31, 2021 are attached as Exhibit 99.1 to this Current Report on Form 8-K /A and are incorporated by reference herein.
(b) Pro Forma Financial Information
The unaudited pro forma condensed combined financial statements and related notes as of and for the year ended December 31, 2021, giving effect to the Acquisition, are attached as Exhibit 99.2 to this Current Report on Form 8-K /A and are incorporated by reference herein.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: May 13, 2022 | Collegium Pharmaceutical, Inc. | |
|---|---|---|
| By: | /s/ Colleen Tupper | |
| Name: Colleen Tupper | ||
| Title: Executive Vice President and Chief Financial Officer |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in:
| · | Registration Statement Nos. 333-234329 and 333-237200 on Form S-3 of Collegium<br>Pharmaceuticals, Inc., and |
|---|---|
| · | Registration Statement Nos. 333-207744, 333-218767, 333-225498, 333-233092,<br>333-245649, and 333-258752 on Form S-8 of Collegium Pharmaceuticals, Inc. |
of our report dated March 9, 2022, relating to the consolidated financial statements of Biodelivery Sciences International, Inc. as of and for the years ended December 31, 2021 and 2020 appearing in this Current Report on Form 8-K/A of Collegium Pharmaceuticals, Inc.
| /s/ Ernst & Young LLP |
|---|
Raleigh, NC
May 13, 2022
Exhibit 23.2
Consent of Independent Registered Public AccountingFirm
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-234329 and 333-237200) and S-8 (No. 333-207744, 333-218767, 333-225498, 333-233092, 333-245649, and 333-258752) of Collegium Pharmaceutical, Inc. of our report dated March 12, 2020 related to the financial statements of BioDelivery Sciences International, Inc. and subsidiaries as of and for the year ended December 31, 2019, which appears in this Current Report on Form 8-K/A.
/s/ Cherry Bekaert LLP
Raleigh, North Carolina
May 13, 2022
Exhibit 99.2
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIALINFORMATION
Introduction
On March 22, 2022, Collegium Pharmaceutical, Inc. (the “Company”) completed the acquisition (the “Acquisition”) of BioDelivery Sciences International, Inc. (“BDSI”), pursuant to an Agreement and Plan of Merger, dated February 14, 2022, by and among the Company, Bristol Acquisition Company Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Purchaser”), and BDSI (the “Merger Agreement”). Upon completion of the Acquisition, BDSI became a wholly owned subsidiary of the Company. The following unaudited pro forma condensed combined statements of operations (pro forma statement of operations) and unaudited condensed combined balance sheet (pro forma balance sheet) and related notes (collectively, the pro forma financial statements) give effect to the Acquisition and were prepared in accordance with the requirements of Article 11 of Regulation S-X.
Accounting for the Acquisition is dependent upon certain information, including valuation reports and other studies, that have not yet been finalized. The Company cannot finalize the accounting for the Acquisition until that information is available in final form. Therefore, the acquired assets and assumed liabilities have been measured based on various preliminary estimates using assumptions that the Company believes are reasonable, utilizing information that is currently available. Differences between these preliminary estimates and the final acquisition accounting could have a material impact on the accompanying pro forma financial statements and the combined company’s future results of operations and financial position. The Company intends to finalize the acquisition accounting as soon as practicable within the required measurement period, but in no event later than one year following completion of the Acquisition, which is March 22, 2023. The Company is not required to, and therefore currently does not intend to, update these pro forma results as presented herein for any of these changes.
The pro forma financial statements set forth below give effect to the Acquisition as well as the application of the acquisition method of accounting. The pro forma financial statements should be read in conjunction with:
| · | The Company's audited consolidated financial statements and related notes<br>included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021; and |
|---|---|
| · | BDSI's audited consolidated financial statements and related notes included<br>in Item 8 within BDSI’s Annual Report on Form 10-K for the year ended December 31, 2021, which are incorporated by reference to<br>this Current Report on Form 8-K/A. |
| --- | --- |
Collegium Pharmaceutical, Inc.
Unaudited Pro Forma Condensed Combined BalanceSheet as of December 31, 2021
(in thousands)
| **** | **** | **** | Historical | **** | **** | **** | **** | **** | **** | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BDSI | Transaction | Pro Forma | |||||||||||
| Historical | (As Adjusted - | Accounting | Combined | ||||||||||
| Collegium | Note 3) | Adjustments | Note 5 | Company | |||||||||
| Assets | |||||||||||||
| Current assets | |||||||||||||
| Cash and cash equivalents | $ | 186,426 | $ | 114,309 | $ | (183,260 | ) | A | $ | 117,475 | |||
| Accounts receivable, net | 105,844 | 56,867 | - | 162,711 | |||||||||
| Inventory | 17,394 | 23,711 | 40,400 | B | 81,505 | ||||||||
| Prepaid expenses and other current assets | 5,879 | 7,178 | - | 13,057 | |||||||||
| Total current assets | 315,543 | 202,065 | (142,860 | ) | 374,748 | ||||||||
| Property and equipment, net | 19,491 | 1,221 | - | 20,712 | |||||||||
| Operating lease assets | 7,644 | 520 | (39 | ) | C | 8,125 | |||||||
| Intangible assets, net | 268,723 | 61,548 | 383,452 | D | 713,723 | ||||||||
| Restricted cash | 2,547 | - | - | 2,547 | |||||||||
| Deferred tax assets | 78,042 | 56,527 | (115,052 | ) | E | 19,517 | |||||||
| Other noncurrent assets | 87 | - | - | 87 | |||||||||
| Goodwill | - | 2,715 | 131,367 | F | 134,082 | ||||||||
| Total assets | $ | 692,077 | $ | 324,596 | $ | 256,868 | $ | 1,273,541 | |||||
| Liabilities and stockholders' equity | |||||||||||||
| Current liabilities | |||||||||||||
| Accounts payable | $ | 4,189 | $ | 8,114 | $ | - | $ | 12,303 | |||||
| Accrued expenses | 29,214 | 21,841 | 6,619 | G | 57,674 | ||||||||
| Accrued rebates, returns and discounts | 196,996 | 47,472 | - | 244,468 | |||||||||
| Current portion of notes payable | 48,353 | 4,615 | 47,032 | H | 100,000 | ||||||||
| Current portion of operating lease liabilities | 814 | 336 | - | 1,150 | |||||||||
| Total current liabilities | 279,566 | 82,378 | 53,651 | 415,595 | |||||||||
| Term notes payable, net of current portion | 61,666 | 54,177 | 412,289 | H | 528,132 | ||||||||
| Convertible senior notes | 139,966 | - | - | 139,966 | |||||||||
| Operating lease liabilities, net of current portion | 7,951 | 219 | (74 | ) | C | 8,096 | |||||||
| Total liabilities | 489,149 | 136,774 | 465,866 | 1,091,789 | |||||||||
| Stockholders' equity: | |||||||||||||
| Common stock | 36 | 104 | (104 | ) | I | 36 | |||||||
| Additional paid-in capital | 502,095 | 455,895 | (455,895 | ) | I | 502,095 | |||||||
| Accumulated deficit | (256,342 | ) | (256,022 | ) | 234,846 | I | (277,518 | ) | |||||
| Treasury stock | (42,861 | ) | (12,155 | ) | 12,155 | I | (42,861 | ) | |||||
| Total stockholders equity | 202,928 | 187,822 | (208,998 | ) | 181,752 | ||||||||
| Total liabilities and stockholders' equity | $ | 692,077 | $ | 324,596 | $ | 256,868 | $ | 1,273,541 |
See Notes to the Unaudited Pro Forma CondensedCombined Financial Statements
Collegium Pharmaceutical, Inc.
Unaudited Pro Forma Condensed Combined Statementof Operations For the Year Ended December 31, 2021
(in thousands, except share and per share data)
| **** | **** | **** | Historical | **** | **** | **** | **** | **** | **** | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BDSI | Transaction | Pro Forma | |||||||||||
| Historical | (As Adjusted - | Accounting | Combined | ||||||||||
| Collegium | Note 3) | Adjustments | Note 5 | Company | |||||||||
| Revenue | |||||||||||||
| Product revenues, net | $ | 276,868 | $ | 164,598 | $ | - | $ | 441,466 | |||||
| Product royalty revenue | - | 2,105 | - | 2,105 | |||||||||
| Total revenue | 276,868 | 166,703 | - | 443,571 | |||||||||
| Cost of product revenues | |||||||||||||
| Cost of product revenues (excluding intangible asset amortization) | 59,070 | 23,373 | 40,400 | AA | 122,843 | ||||||||
| Intangible asset amortization | 67,181 | 7,284 | 77,840 | BB | 152,305 | ||||||||
| Total cost of product revenues | 126,251 | 30,657 | 118,240 | 275,148 | |||||||||
| Gross profit | 150,617 | 136,046 | (118,240 | ) | 168,423 | ||||||||
| Operating expenses | |||||||||||||
| Research and development | 9,451 | - | - | 9,451 | |||||||||
| Selling, general and administrative | 118,960 | 98,922 | 21,176 | CC | 239,058 | ||||||||
| Restructuring | 4,578 | - | - | 4,578 | |||||||||
| Total operating expenses | 132,989 | 98,922 | 21,176 | 253,087 | |||||||||
| Income (loss) from operations | 17,628 | 37,124 | (139,416 | ) | (84,664 | ) | |||||||
| Interest expense | (21,014 | ) | (7,536 | ) | (40,130 | ) | DD | (68,680 | ) | ||||
| Interest income | 12 | 40 | - | 52 | |||||||||
| Other expense | - | (6 | ) | - | (6 | ) | |||||||
| (Loss) income before taxes | (3,374 | ) | 29,622 | (179,546 | ) | (153,298 | ) | ||||||
| Benefit from income taxes | 74,891 | 55,238 | 46,682 | EE | 176,811 | ||||||||
| Net income | $ | 71,517 | $ | 84,860 | $ | (132,864 | ) | $ | 23,513 | ||||
| Earnings per share - basic | $ | 2.05 | $ | 0.67 | |||||||||
| Weighted-average shares - basic | 34,936,817 | 34,936,817 | |||||||||||
| Earnings per share - diluted | $ | 1.86 | $ | 0.65 | |||||||||
| Weighted-average shares - diluted | 41,045,805 | 36,120,671 |
See Notes to the Unaudited Pro Forma CondensedCombined Financial Statements
NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
Note 1 - Description of the Transaction
On March 22, 2022 (the “Closing Date”), Collegium Pharmaceutical, Inc. (the “Company” or “Collegium”) completed its purchase of all of the outstanding equity of BioDelivery Sciences International, Inc. (“BDSI”), a specialty pharmaceutical company working to deliver innovative therapies for individuals living with serious and debilitating chronic conditions (the “Acquisition”), pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), dated as of February 14, 2022, by and among the Company, Bristol Acquisition Company Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Purchaser”), and BDSI, a Delaware corporation. Upon completion of the Acquisition, BDSI became a wholly owned subsidiary of the Company.
Total consideration for the Acquisition was approximately $669.4 million, consisting of (i) $606.4 million of cash paid to BDSI stockholders (equivalent to $5.60 per share of common stock), including previously outstanding common stock ($578.1 million) as well as outstanding restricted stock units and in-the-money options ($28.3 million), and (ii) $63.0 million of cash paid for BDSI’s debt not assumed by the Company.
Note 2 – Basis of Presentation
The unaudited pro forma financial statements show the historical financial positions and results of operations of Collegium and BDSI and have been prepared to illustrate the effect of the Acquisition, including pro forma assumptions and adjustments related to the Acquisition, as described in these accompanying notes.
The acquisition of BDSI is considered an acquisition of a business, as defined in Accounting Standards Codification (“ASC”) Topic 805, Business Combinations. Therefore, the unaudited pro forma financial statements have been prepared using the acquisition method of accounting in accordance with ASC 805, which generally requires the acquired assets and assumed liabilities to be recognized at fair value at Closing Date. The pro forma statements of operations and pro forma balance sheet may differ from the Company's final purchase accounting for a number of reasons, including the fact that the estimates of fair values of assets acquired and liabilities assumed as of the Closing Date are preliminary and therefore subject to change within the measurement period (up to one year from the Closing Date), at which time the valuation analysis and other studies are finalized. The preliminary purchase price allocation is discussed in Note 4.
Certain reclassifications have been made to the historical presentation of BDSI’s financial statements in order to conform to the financial statement presentation of the Company. These reclassifications are discussed further in Note 3.
The pro forma balance sheet as of December 31, 2021 is presented as if the Acquisition occurred on December 31, 2021. The pro forma statement of operations is presented as if the Acquisition occurred on January 1, 2021. The historical consolidated financial information has been adjusted on a pro forma basis for transaction accounting adjustments as defined within Article 11 of Regulation S-X.
The unaudited pro forma financial statements are provided for illustrative purposes only, and do not purport to represent what the actual consolidated results of the companies would have been had the Acquisition occurred on January 1, 2021 or December 31, 2021, nor are they necessarily indicative of future consolidated results of operations of the Company. The pro forma statement of operations neither reflect the costs of any integration activities nor the synergies and benefits that may result from realization of any operational efficiencies expected to result from the Acquisition of BDSI. The Company has estimated that at least $75 million of annual run rate cost synergies are expected to be realized within twelve months after the combination as a result of reduced headcount and other management actions to consolidate operations and reduce costs.
Note 3 – Reclassification Adjustments
Certain balances were reclassified from the historical BDSI financial statement presentation so that their presentation would be consistent with that of the Company. These adjustments and reclassifications are based on management’s preliminary analysis. Refer to the table below for a summary of reclassification adjustments made to present BDSI’s consolidated balance sheet as of December 31, 2021 to conform with that of the Company (in thousands):
| Historical | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| BDSI | Reclassification | Adjusted | ||||||||
| BDSI Line Item | Collegium Line Item | (As Reported) | Adjustments | Note | BDSI | |||||
| Noncurrent assets: | ||||||||||
| Property and equipment, net | Property and equipment, net | $ | 1,741 | $ | (520 | ) | 1 | $ | 1,221 | |
| Operating lease assets | - | 520 | 1 | 520 | ||||||
| Current liabilities: | ||||||||||
| Accounts payable and accrued liabilities | Accounts payable | 77,763 | (69,649 | ) | 2,<br> 3,<br> 4 | 8,114 | ||||
| Accrued expenses | - | 21,841 | 3 | 21,841 | ||||||
| Accrued rebates, returns and discounts | - | 47,472 | 4 | 47,472 | ||||||
| Current portion of operating lease liability | - | 336 | 2 | 336 | ||||||
| Noncurrent liabilities: | ||||||||||
| Other long-term liabilities | 219 | (219 | ) | 2 | - | |||||
| Operating lease liabilities, net of current portion | - | 219 | 2 | 219 | ||||||
| (1) | Reclassified operating lease right of use assets to a separate line from property and equipment, net to conform to the Company’s<br>presentation. | |||||||||
| --- | --- | |||||||||
| (2) | Reclassified operating lease liabilities to separate lines from accounts payable and accrued liabilities and other long-term liabilities<br>for the current and noncurrent portions, respectively. | |||||||||
| --- | --- | |||||||||
| (3) | Reclassified accrued liabilities to a separate line from accounts payable and accrued liabilities. | |||||||||
| --- | --- | |||||||||
| (4) | Reclassified accrued rebates, returns and discounts to a separate line from accounts payable and accrued liabilities. | |||||||||
| --- | --- |
Refer to the table below for a summary of reclassification adjustments made to present BDSI’s consolidated statement of operations for the year ended December 31, 2021 to conform with that of the Company (in thousands):
| Historical | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BDSI | Reclassification | Adjusted | ||||||||||
| BDSI Line Item | Collegium Line Item | (As Reported) | Adjustments | Note | BDSI | |||||||
| Cost of product sales: | ||||||||||||
| Intangible asset amortization | $ | - | $ | 7,284 | 1 | $ | 7,284 | |||||
| Operating expenses: | ||||||||||||
| Selling, general and administrative | Selling, general and administrative | 106,206 | (7,284 | ) | 1 | 98,922 | ||||||
| Other income (expense): | ||||||||||||
| Interest income | - | 40 | 2 | 40 | ||||||||
| Interest expense, net of interest income | Interest expense | (7,496 | ) | (40 | ) | 2 | (7,536 | ) | ||||
| (1) | Reclassified intangible asset amortization to a separate line from selling, general and administrative expense. | |||||||||||
| --- | --- | |||||||||||
| (2) | Reclassified interest income from interest expense, net of interest income. | |||||||||||
| --- | --- |
Note 4 - Purchase Price Accounting and Related Adjustments
The Company expects to finalize its purchase price allocation within one year of the Closing Date. In addition, the Company continues to analyze and assess relevant information necessary to determine, recognize and record the purchase price including the fair value of the assets acquired and liabilities assumed primarily related to intangible assets, inventories, tax assets and liabilities, and certain existing or potential reserves, such as those for legal or revenue adjustments. The activities the Company is currently undertaking include, but are not limited to, review of acquired contracts and other contract-related and legal matters, review and evaluation of the accounting policies, tax positions, and other tax-related matters. Further, the Company is using a third-party valuation firm to assist management in determining the fair value of the acquired tangible and intangible assets, and other information necessary to record and measure the assets acquired and liabilities assumed. Accordingly, the preliminary recognition and measurement of assets acquired and liabilities assumed as of the Closing Date is subject to change and such changes may be material.
The following table presents the Company’s preliminary estimates of the fair values of the assets acquired and liabilities assumed as if the Acquisition occurred as of December 31, 2021 (in thousands):
| **** | **** | Pro Forma Amounts Recognized at the Acquisition Date |
|---|---|---|
| Assets Acquired | ||
| Cash and cash equivalents | $ | 96,924 |
| Accounts receivable | 56,867 | |
| Inventory | 64,111 | |
| Prepaid expenses and other current assets | 7,178 | |
| Property and equipment | 1,221 | |
| Operating lease assets | 481 | |
| Intangible assets | 445,000 | |
| Total assets | $ | 671,782 |
| Liabilities Assumed | ||
| Accounts payable | $ | 8,114 |
| Accrued expenses | 21,841 | |
| Accrued rebates, returns and discounts | 47,472 | |
| Operating lease liabilities | 481 | |
| Deferred tax liabilities | 58,525 | |
| Total liabilities | $ | 136,433 |
| Total identifiable net assets acquired | 535,349 | |
| Goodwill | 134,082 | |
| Total consideration transferred | $ | 669,431 |
Note 5 - Pro Forma Adjustments
The pro forma adjustments are based on the Company’s preliminary estimates and assumptions that are subject to change. The following adjustments have been reflected in the Pro Forma Financial Statements:
Balance Sheet Pro Forma Adjustments
| (A) | Represents cash utilized in the transaction, including $151.3 million of cash paid for outstanding common stock of BDSI (remainder<br>of cash paid for common stock was funded through proceeds of a new term note), $17.4 million of BDSI closing costs, and $14.6 million<br>of Collegium closing costs. |
|---|---|
| (B) | Reflects adjustments of $40.4 million to the historical BDSI inventory to increase the balance to its estimated fair value. |
| --- | --- |
| (C) | Represents adjustments to the lease liability and corresponding right of use asset to record the lease liability to fair value. |
| --- | --- |
| (D) | Reflects adjustments of $383.5 million of historical intangible assets to increase the balance to its estimated fair value. The composition<br>of the intangible asset adjustment and the estimate life is discussed below in Note BB. The estimate of fair value may differ from amounts<br>the Company will calculate after completing a detailed valuation analysis and the difference could have a material effect on the accompanying<br>unaudited pro forma financial statements. |
| --- | --- |
| (E) | Reflects the recognition of income tax assets and liabilities resulting primarily from preliminary fair value adjustments and deferred<br>tax assets from acquired net operating loss carryforwards. The estimate of deferred tax assets and liabilities was determined using the<br>estimated statutory rate of 26.0%. |
| --- | --- |
| (F) | Represents the net increase in goodwill resulting from the Acquisition after elimination of the BDSI historical goodwill. |
| --- | --- |
| (G) | Represents $6.6 million of accrued employee severance-related expenses. The Company recorded post-combination severance and other<br>separation benefits in connection with the termination of employees immediately after acquisition. |
| --- | --- |
| (H) | Reflects the modification of the existing Collegium term loan to increase the term loan to $650.0 million, which net of existing and<br>new debt discounts is $628.1 million. The BDSI term loan was paid at closing and was $60.0 million before debt discounts as of December<br>31, 2021. |
| --- | --- |
| (I) | Reflects the elimination of BDSI common stock, additional paid-in capital, treasury stock, and accumulated deficit. Adjustments to<br>accumulated deficit also include adjustments to reflect transaction costs and severance accrual previously discussed. |
| --- | --- |
Statement of Operations Pro Forma Adjustments
(AA) Represents the adjustment to cost of product revenues to reflect the increase to the historical inventory value to its estimated fair value. Historic inventory turnover is less than one year and therefore the entire fair value adjustment for inventory acquired is reflected as cost of product revenues in the period.
(BB) Represents the adjustment to reflect amortization of the acquired intangible assets utilizing a straight-line method, net of amortization expense historically recognized by BDSI of $7.3 million. Amortization expense is based on the following fair value (in thousands):
| Amortization Period | ||||||
|---|---|---|---|---|---|---|
| (Years) | Fair Value | Amortization Expense | ||||
| Belbuca | 4.8 | $ | 370,000 | $ | 77,487 | |
| Symproic | 9.6 | 70,000 | 7,285 | |||
| Elyxyb | 14.2 | 5,000 | 352 | |||
| Total | $ | 445,000 | $ | 85,124 |
(CC) Represents recognition of the Company’s acquisition related transaction costs of $14.6 million as well as the recognition of employee severance-related expense of $6.6 million discussed in Note G above.
(DD) Represents the net increase in interest expense as a result the $650.0 million term loan, which resulted from a modification of the existing Collegium term loan and the reduction of the historic BDSI interest expense as a result of the payoff by BDSI of its term loan at the Closing Date.
(EE) Represents the income tax effect of the Acquisition pro forma adjustments using an estimated statutory rate of 26.0%.